about
Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infectionsAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsRecent developments in antibacterial drug discovery: microbe-derived natural products--from collection to the clinic.Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England.Rapid development of Acinetobacter baumannii resistance to tigecycline.Drug treatment for multidrug-resistant Acinetobacter baumannii infections.Tigecycline: a novel broad-spectrum antimicrobial.Antimicrobial susceptibilities of Brucella isolates from various clinical specimensTigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Current and novel antibiotics against resistant Gram-positive bacteriaDistribution of quinolones, sulfonamides, tetracyclines in aquatic environment and antibiotic resistance in indochina.Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues.The ribosomal S10 protein is a general target for decreased tigecycline susceptibilityIn vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.Global challenge of multidrug-resistant Acinetobacter baumanniiAdjunctive Hyperbaric Oxygen Therapy or Alone Antibiotherapy? Methicillin Resistant Staphylococcus aureus Mediastinitis in a Rat Model.Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance ProgramClinical and economic impact of common multidrug-resistant gram-negative bacilliIn vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in ItalyMultiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.Investigational treatments for postoperative surgical site infections.The current state of multidrug-resistant gram-negative bacilli in North America.Synthesis and antibacterial activity of doxycycline neoglycosides.Current challenges in treating MRSA: what are the options?Clinical significance of extended-spectrum beta-lactamases.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Tigecycline: a new treatment option for intra-abdominal infections.Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.Newer developments in the treatment of Gram-positive infections.Quinolone and cephalosporin resistance in enteric Fever.Prophylaxis and treatment of infections associated with penetrating traumatic injury.Current treatment for nocardia infections.Tigecycline exerts an antitumoral effect in oral squamous cell carcinoma.Novel antibiotics for the treatment of Staphylococcus aureus.In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria.Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo.In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited.Retrospective analysis of tigecycline shows that it may be an option for children with severe infections.
P2860
Q26991886-41B90274-03E8-4C88-B000-C7999A4236BEQ27015109-41A1ECC8-11B0-4D47-B7AF-C0A94D516517Q33234858-9503EAA6-52B3-468F-86BF-E53597F26DE5Q34571574-4F9806BB-24FC-45DA-96AC-4F06F852D943Q34581377-75074D7A-24AF-4F7B-B790-BF635F59E8EBQ34601684-B178EF74-F6EC-4029-A334-FB218E88C434Q34630833-E7064ED6-E2DD-420D-AB66-50A4BFEB85C5Q34648259-E1FFB4F4-F343-49D4-80DB-FA76170531F3Q34803735-1A715DA5-35DA-47C9-880B-6218B64BFA07Q35026521-1E1E57A0-DFFF-4D0A-87E8-14440BDAF046Q35770105-515E8255-887B-4D5C-9806-CACD343E5ADDQ35778366-35242C89-5084-42D9-8CEB-E9E28EEC7667Q35960763-7AD7B445-EAC1-4DDB-BE8A-B8801A8E45CAQ36064268-8E7DBFC2-3B14-4171-BD03-FD867ADAFB0FQ36095081-C7DD84B3-1ADD-43B8-9F57-0E6F970E8052Q36402879-3A67D92F-BC13-4482-A446-E2C0E5298C4FQ36425049-4D3EC49C-2CC3-40AB-813B-87FCC2D0B75EQ36482801-2D8D2A66-D2DF-47DB-B0B7-36DC4F2F6955Q36509591-4C6F6474-8E16-4352-ADFC-0A191D9F423FQ36571962-1D0E17C3-CA6C-4AB2-90A7-16DDC7600D76Q36612595-B2A58C99-C806-4B61-AA9A-589EC964356EQ36715742-B06D1D7F-09ED-489D-8C8C-25A802046C22Q37069191-E09AF7D0-1B2F-4D2D-9074-5DE37C46377EQ37270510-B7BDD10D-6B83-4309-813C-DA8776C6B744Q37291338-5C2AC89B-75B4-49B8-A9FA-79B7E4220A17Q37291354-45FBEDB9-7FE3-418B-B4A7-28B44E51C576Q37377897-CFA1C51B-5F43-4BAF-B005-AAC4209C4126Q37557860-1B2E4F77-17E6-4312-A254-23C2D80E9CA5Q37608268-F7B7BD5C-6FB0-4414-AF08-ADDB54B1D012Q37636151-8659FC89-4BC0-4530-99D6-E4E883570865Q37798457-34A47C03-C8CB-4136-9078-0E0893149583Q37822456-AE55E59F-4521-4D90-93BB-6A3ED311A456Q38149157-FA6F33AA-4BC8-4E88-8D56-24FE5EB5BF6AQ38920797-A066A8C5-2AB1-460D-B5B7-12744D8D49BFQ39933945-8E9BE029-055F-4E0B-B3C4-CC46495637D2Q40108198-B9009E2C-CF86-4294-9964-F14866A83D46Q40188774-5D56E8BE-1346-4101-8A91-71D00C9B79F3Q40241381-86FAD1AF-5CCE-4CBD-9FA6-1703CBBCCD56Q40423903-FDB5F5DF-0BF4-4CD1-B273-E90C3BEB0C38Q40624454-C8658A8E-7B66-4DB8-B510-10F8E1C8A857
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tigecycline: what is it, and where should it be used?
@ast
Tigecycline: what is it, and where should it be used?
@en
Tigecycline: what is it, and where should it be used?
@nl
type
label
Tigecycline: what is it, and where should it be used?
@ast
Tigecycline: what is it, and where should it be used?
@en
Tigecycline: what is it, and where should it be used?
@nl
prefLabel
Tigecycline: what is it, and where should it be used?
@ast
Tigecycline: what is it, and where should it be used?
@en
Tigecycline: what is it, and where should it be used?
@nl
P356
P1476
Tigecycline: what is it, and where should it be used?
@en
P2093
David M Livermore
P356
10.1093/JAC/DKI291
P407
P577
2005-10-01T00:00:00Z